Cybin Insider Trading
NEO HELP
1
All Trades
1
Significant
0
Notable
0
Clusters
0
Repeat
| Company | Insider | Title | Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|
| Cybin | ██████ | ████████ | ██-███-26 | ███,███ | $█.██ | $███,███ | ███,███ | ██% | ████████ |
| Company | Insider | Title | Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|
| Cybin | Fahel, Gabriel | Chief Legal Officer | 02-Sep-25 | 9,000 | $8.93 | $80,370 | 10,316 | 684% | Significant |
Stock Chart
Related Companies to Explore
Company Info
Cybin is a clinical-stage biopharmaceutical company developing psychedelic-based therapeutics for mental health disorders. The company operates primarily in Canada and the United States, with headquarters in Toronto and operations in New York. Cybin focuses on developing novel formulations and delivery methods for psychedelic compounds, particularly psilocybin and DMT derivatives, to treat conditions including major depressive disorder, anxiety disorders, and addiction.
The company’s lead drug candidate is CYB003, a proprietary deuterated psilocybin analog designed for the treatment of major depressive disorder. Cybin has also developed CYB004, a deuterated DMT molecule being investigated for treating anxiety disorders. The company operates its own manufacturing facility in the Netherlands to produce psychedelic compounds for research and clinical use. Cybin has established partnerships with academic institutions and research organizations to advance its clinical programs.
The company has completed Phase I clinical trials for multiple compounds and advanced several programs into Phase II trials. Cybin holds various patents related to psychedelic drug formulations and delivery systems. The company was founded in 2019 and has raised significant funding to support its research and development activities in the emerging field of psychedelic medicine.